Technical Analysis for GMAB - Genmab A/S

Grade Last Price % Change Price Change
F 33.83 -3.67% -1.29
GMAB closed down 3.67 percent on Tuesday, March 2, 2021, on 1.18 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical GMAB trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish -3.67%
Slingshot Bearish Bearish Swing Setup -3.67%
Calm After Storm Range Contraction -3.67%
Narrow Range Bar Range Contraction -3.67%
NR7 Range Contraction -3.67%
Lower Bollinger Band Walk Weakness -3.67%
Older End-of-Day Signals for GMAB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1 ATR about 22 hours ago
60 Minute Opening Range Breakdown about 22 hours ago
2x Volume Pace about 23 hours ago
Down 3% about 23 hours ago
Lower Bollinger Band Support about 23 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Genmab A/S Description

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.


Sector: Healthcare
Industry: Long-Term Care Facilities
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Drugs Treatment Of Cancer Antibodies Monoclonal Antibodies Monoclonal Antibody Lymphoma Genetics Acute Myeloid Leukemia Non Small Cell Lung Cancer Immunotherapies Parkinson's Disease Multiple Sclerosis Multiple Myeloma Amyloid Antibody Drug Conjugates Chronic Lymphocytic Leukemia Lymphocytic Leukemia Amyloidosis Breakthrough Therapy Copenhagen Camidanlumab Tesirine Cd20 Advanced Cancer Orphan Drugs Treatment Of Chronic Lymphocytic Leukemia Advanced Cancers Genmab Solid Cancers

Is GMAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 44.83
52 Week Low 16.24
Average Volume 560,159
200-Day Moving Average 36.48
50-Day Moving Average 40.23
20-Day Moving Average 38.68
10-Day Moving Average 36.80
Average True Range 1.23
ADX 28.07
+DI 13.39
-DI 44.75
Chandelier Exit (Long, 3 ATRs ) 38.26
Chandelier Exit (Short, 3 ATRs ) 37.03
Upper Bollinger Band 44.11
Lower Bollinger Band 33.24
Percent B (%b) 0.05
BandWidth 28.09
MACD Line -1.74
MACD Signal Line -1.06
MACD Histogram -0.6769
Fundamentals Value
Market Cap 22.17 Billion
Num Shares 655 Million
EPS 33.19
Price-to-Earnings (P/E) Ratio 1.02
Price-to-Sales 14.12
Price-to-Book 8.39
PEG Ratio 2.10
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.85
Resistance 3 (R3) 34.94 34.69 34.68
Resistance 2 (R2) 34.69 34.43 34.65 34.62
Resistance 1 (R1) 34.26 34.27 34.14 34.17 34.57
Pivot Point 34.01 34.01 33.95 33.97 34.01
Support 1 (S1) 33.58 33.75 33.46 33.49 33.09
Support 2 (S2) 33.33 33.59 33.29 33.04
Support 3 (S3) 32.90 33.33 32.98
Support 4 (S4) 32.81